Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs

被引：61

作者：

Damdinsuren, B ^{[1
]}

Nagano, H ^{[1
]}

Sakon, M ^{[1
]}

Kondo, M ^{[1
]}

Yamamoto, T ^{[1
]}

Umeshita, K ^{[1
]}

Dono, K ^{[1
]}

Nakamori, S ^{[1
]}

Monden, M ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol E2, Osaka 5650871, Japan

来源：

ANNALS OF SURGICAL ONCOLOGY | 2003年 / 10卷 / 10期

关键词：

interferon; anticancer drug; cell proliferation; HCC; combination therapy;

D O I：

10.1245/ASO.2003.03.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor, but promising effects of chemotherapies combined with interferon (IFN) have been reported. Methods: To develop more effective combination therapies for HCC, we compared the antiproliferative effects of IFN-alpha and IFN-beta in combination with various cytotoxic drugs on hepatoma cell lines using MTT assay and isobologram analysis. Results: IFN-beta was more potent than IFN-alpha in inhibiting the cell growth of all cell lines (P <.05, two-way ANOVA). PLC/PRF/5 was more sensitive to either IFN, than HLE and HuH7. Cell growth of all cell lines was inhibited in a dose-dependent manner by 5-fluorouracil (5-FU), cisplatin (CDDP), and doxorubicin (DOX), but the sensitivities of these cells were considerably different. As for IFN-α, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-β showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/ PRF/5 cell lines. Conclusion: The spectra of the antiproliferative activity and synergistic effect of IFN-β when combined with anticancer drugs are more potent than those of IFN-α. Combinations of IFN-β and anticancer drugs may provide a better treatment of HCC when combinations with IFN-α are ineffective.

引用

页码：1184 / 1190

页数：7

共 26 条

[1] Hepatocellular carcinoma: an overview [J].

Anthony, PP .

HISTOPATHOLOGY, 2001, 39 (02) :109-118

[2] CRITERIA FOR ANALYZING INTERACTIONS BETWEEN BIOLOGICALLY-ACTIVE AGENTS [J].

BERENBAUM, MC .

ADVANCES IN CANCER RESEARCH, 1981, 35 :269-335

[3] Epidemiology of primary liver cancer [J].

Bosch, FX ;

Ribes, J ;

Borràs, J .

SEMINARS IN LIVER DISEASE, 1999, 19 (03) :271-285

[4]

Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821

[5]

CORADINI D, 1994, ANTICANCER RES, V14, P1779

[6]

Eguchi H, 2000, CLIN CANCER RES, V6, P2881

[7]

Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619

[8]

Horikoshi Takashi, 1995, Journal of Dermatology (Tokyo), V22, P631

[9] Hepatocellular carcinoma: is current therapy really altering outcome? [J].

Johnson, PJ .

GUT, 2002, 51 (04) :459-462

[10] Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities [J].

Jonasch, E ;

Haluska, FG .

ONCOLOGIST, 2001, 6 (01) :34-55

← 1 2 3 →